Kevin Tan sells SLDB shares, RSUs settle (SLDB) — January–February 2026

Rhea-AI Filing Summary

Solid Biosciences reported insider sale activity by Kevin Tan: reported sales include 5,704 shares for $30,060.08 on 01/13/2026, 26,837 shares for $172,747.09 on 02/02/2026, and 14,783 shares for $95,226.63 on 02/04/2026. The filing also records 5,404 shares associated with settlement of vested restricted stock units on 02/18/2026.

Insights

Equity Compensation Analyst

Insider sales reported across January–February 2026 involving vested RSU settlement.

The excerpt lists specific open-market dispositions: 5,704 shares ($30,060.08) on 01/13/2026, 26,837 shares ($172,747.09) on 02/02/2026, and 14,783 shares ($95,226.63) on 02/04/2026. It also records 5,404 shares from the settlement of vested restricted stock units on 02/18/2026.

These items reflect routine compensation-related activity and reported dispositions by the named individual. The cash‑flow counterparties and whether sales were pre‑planned are not stated in the excerpt; subsequent filings may clarify method or purpose.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	5404	31469.11	83412695	02/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/18/2026	Settlement of vested restricted stock units	Issuer			5404	02/18/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Tan Kevin C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	01/13/2026	5704	30060.08
Tan Kevin C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/02/2026	26837	172747.09
Tan Kevin C/O SOLID BIOSCIENCES INC. 500 Rutherford Avenue Charlestown MA 02129	Common Stock	02/04/2026	14783	95226.63

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider transactions does SLDB Form 144 report for Kevin Tan?

The filing shows reported sales of 5,704 shares ($30,060.08) on 01/13/2026, 26,837 shares ($172,747.09) on 02/02/2026, and 14,783 shares ($95,226.63) on 02/04/2026. It also notes 5,404 shares settled from vested RSUs on 02/18/2026.

Does the filing indicate why the RSUs were settled on 02/18/2026 for SLDB?

The excerpt states the 5,404 shares on 02/18/2026 are a settlement of vested restricted stock units and lists the issuer as the source. No additional rationale or payment details are provided in the excerpt.

Who is the reporting person in the SLDB Form 144 excerpt?

The reporting person named is Kevin Tan with an address listed at Solid Biosciences' Charlestown location. The excerpt ties the listed sale transactions and RSU settlement to that individual.

Are the sale proceeds or recipients specified for the SLDB transactions?

The excerpt provides gross proceeds for each sale: $30,060.08, $172,747.09, and $95,226.63. It does not specify purchasers, brokers, or whether proceeds went to the reporting person or another party.